Open Medicine (Jan 2024)

EDNRB inhibits the growth and migration of prostate cancer cells by activating the cGMP-PKG pathway

  • Li Xun,
  • Liu Bide,
  • Wang Shuheng,
  • Dong Qiang,
  • Li Jiuzhi

DOI
https://doi.org/10.1515/med-2023-0875
Journal volume & issue
Vol. 19, no. 1
pp. 10627 – 37

Abstract

Read online

Prostate cancer (PCa) represents a substantial global health concern and a prominent contributor to male cancer-related mortality. The aim of this study is to explore the role of B-type endothelin receptor (EDNRB) in PCa and evaluate its therapeutic potential. The investigation employed predictive methodologies encompassing data acquisition from the GEO and TCGA databases, gene screening, enrichment analysis, in vitro experiments involving PCR, Western blotting, wound healing, and Transwell assays, as well as animal experiments. Analysis revealed a significant downregulation of EDNRB expression in PCa cells. Overexpression of EDNRB demonstrated inhibitory effects on tumor cell growth, migration, and invasion, likely mediated through activation of the cGMP-Protein Kinase G pathway. In vivo experiments further confirmed the tumor-suppressive properties of EDNRB overexpression. These findings underscore the prospect of EDNRB as a therapeutic target for PCa, offering novel avenues for PCa treatment strategies.

Keywords